Lale Kostakoglu Shields, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Weill Medical College of Cornell University - New York NY
Rank: Associate Professor
Years: 2000-2006

Mount Sinai School Of Medicine Of New York University - New York NY
Rank: Full Professor
Years: 2006-2019

University Of Virginia School Of Medicine - Charlottesville VA
Rank: Full Professor
Years: 2019-2023

New York University School Of Medicine - New York NY
Rank: Full Professor
Years: 2023-present

Hacettepe University Medical Faculty, Turkey
Rank: Associate Professor
Years: 1994-1999

PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma..
PET Clin.
2019;14:317-329
Date: 01 2019

. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.
Leuk Lymphoma.
2017;58: 372-381
Date: 01 2019

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy
PLoS One.
2018, 14;13(6):e0198548.
Date: 01 2019

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Blood
2018;132:1013-1021.
Date: 01 2019

End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma.
PET Clin.
2019;14:307
Date: 01 2019

Metabolic Tumor Volume: We still need a Platinum-Standard Metric:
J Nucl Med
2017; 58: 196-197
Date: 01 2019

Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT.
J Nucl Med
. 2017;58:1596-1602.
Date: 01 2019

The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
J Urol
2019;201:322-331.
Date: 01 2019